Mannheimer Onkologie Praxis — Clinical Trial Site

10 Registered trials

4 Currently recruiting

Organisation

Mannheimer Onkologie Praxis

Location

Mannheim, Germany

Identifier

ORL-000000263

Address

Q5, 14-22, 68161, Germany

Departments

Hämatologie/Onkologie
Hämatologische und onkologische Schwerpunktpraxis
hämatologischen und onkologischen Schwerpunktpraxis
Mannheimer Onkologie Praxis
n/a
Onkologie Praxis
Q5

Clinical trials at this site (10)

Search interface

Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed Pending

2024-511054-50-00 HIV-1 Infection 10
A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-c… Recruiting

2023-507402-13-00 Multiple myeloma 5 2024-04-03
A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZU… Recruiting

2023-506414-46-00 High risk patients defined as having at least one of th 5 2022-04-22
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (… Recruiting

2023-510294-34-00 small lymphocytic lymphoma (SLL) 5 2025-06-12
Prospective, placebo-controlled clinical trial with Aconite Pain Oil in oncological patients under-going chemotherapy to prevent chemotherap… Recruiting

2022-502889-24-00 chemotherapy-induced polyneuropathy (CIPN) 5 2024-02-13
A phase II, open-label, single arm study to evaluate the efficacy of Luspatercept in Erythropoiesis-stimulating agent naive lower-risk MDS p… Ended

2024-516438-36-00 Patients with very low, low or intermediate risk myelod 4 2022-09-13
Daratumumab for first line treatment of transplant-ineligible myeloma patients followed by daratumumab re-treatment at first relapse (GMMG-D… Ended

2024-517761-17-00 Multiple Myeloma 4 2021-05-31
A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab… Ended

2022-500439-35-00 treatment-naive chronic lymphocytic leukemia 5 2021-02-11
Copanlisib and Rituximab in Marginal Zone Lymphoma Patients - A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (COUP-1) Ended

2022-500674-34-00 Marginal Zone Lymphoma 4 2019-11-04
A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous… Ended

2024-516300-41-00 Multiple Myeloma 5 2023-03-07